- ►natap.org [PDF] T Poynard, J McHutchison, M Manns, C Trepo, … - Gastroenterology, 2002 - Elsevier Necrosis and inflammation improvement ranged from 39% (interferon 24 weeks) to
73% (optimized PEG 1.5 and ribavirin; P < 0.001). Fibrosis worsening ranges from
23% (interferon 24 weeks) to 8% (optimized PEG 1.5 and ribavirin; P < ... Cited by 528 - Related articles - BL Direct - All 17 versions
JL Dienstag, RD Goldin, EJ Heathcote, HWL … - Gastroenterology, 2003 - enrique.isa-geek.com JULES L. DIENSTAG,* ROBERT D. GOLDIN,‡ E. JENNY HEATHCOTE,§ HWL HANN, MARY
WOESSNER,¶ SALLY L. STEPHENSON,¶ STEPHEN GARDNER,¶ D. FRASER GRAY,¶ and
EUGENE R. SCHIFF# *Gastrointestinal Unit (Medical Services), Massachusetts ... Cited by 522 - Related articles - BL Direct - All 10 versions
- ►liver-nash.com [PDF] SL Friedman - Journal of hepatology, 2003 - Elsevier In view of this remarkable progress, clinicians must now view liver fibrosis in
a new light as a clinical problem in its own right amenable to specific
diagnostic tests and therapies that are independent of the etiology. In ... Cited by 491 - Related articles - All 7 versions
KL Lindsay, C Trepo, T Heintges, ML … - Hepatology, 2001 - natap.org This international, randomized, active-controlled, paral- lel-group,
double-blind dose-finding study compared pegin- terferon alfa-2b (PegIntron™)
to interferon alfa-2b for the initial treatment of compensated chronic ... Cited by 477 - Related articles - BL Direct - All 6 versions
- ►temple.edu [PDF] T Poynard, MF Yuen, V Ratzin, CL Lai - The Lancet, 2003 - Elsevier More than 170 million people worldwide are chronically infected with the
hepatitis C virus (HCV), which is responsible for more than 100 000 cases of
liver cancer per year, with similar numbers of digestive haemorrhage and ... Cited by 375 - Related articles - All 11 versions
- ►annals.org [PDF] MS Sulkowski, DL Thomas - Annals of internal medicine, 2003 - Am Coll Physicians Because of shared routes of transmission, hepatitis C virus (HCV) infection is
common in HIV-infected persons, who have been experiencing increasing
HCV-related morbidity and mortality since the advent of effective ... Cited by 281 - Related articles - BL Direct - All 8 versions
R Bataller, DA Brenner - Seminars in liver disease, 2001 - thieme-connect.com Following chronic liver injury of any etiology, there is progressive fibrosis.
To date, removing the causative agent is the only effective therapy to stop or
even reverse liver fibrosis. Therefore, the development of effective ... Cited by 245 - Related articles - BL Direct - All 5 versions
T Poynard, J McHutchison, M Manns, RP Myers … - Hepatology, 2003 - hepatitis-central.com Liver fibrosis and activity indexes were validated in patients infected by
hepatitis C virus (HCV) nontreated and treated by interferon. The aim was to
validate their usefulness as surrogate markers of histologic features using ... Cited by 165 - Related articles - View as HTML - All 4 versions
JL Dienstag, JG McHutchison - Gastroenterology, 2006 - Elsevier In the United States, hepatitis C virus (HCV) infection accounts for
approximately 40% of all chronic liver disease, results in an estimated
8000–10,000 deaths annually, and is the most frequent indication for ... Cited by 161 - Related articles - All 17 versions
- ►annals.org [PDF] S Kubo, S Nishiguchi, K Hirohashi, H Tanaka, … - Annals of internal medicine, 2001 - Am Coll Physicians Background: Interferon therapy decreases the incidence of hep- atocellular
carcinoma in patients with chronic hepatitis C. Objective: To evaluate effects
of interferon- on recurrence after resection of hepatitis C virus–related ... Cited by 159 - Related articles - BL Direct - All 5 versions
